Clinical trials
Atypical Hemolytic Uremic Syndrome trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
45 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2009 | 6 |
| 2010 | 3 |
| 2012 | 3 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 4 |
| 2019 | 1 |
| 2021 | 5 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 5 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 19 |
| Recruiting | 12 |
| Terminated | 4 |
| Withdrawn | 3 |
| Active, not recruiting | 3 |
| Unknown status | 2 |
| Available | 1 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Alexion Pharmaceuticals, Inc. | 16 |
| Mario Negri Institute for Pharmacological Research | 4 |
| AstraZeneca | 3 |
| Novartis Pharmaceuticals | 3 |
| Hoffmann-La Roche | 2 |
| Omeros Corporation | 2 |
| AO GENERIUM | 1 |
| Alnylam Pharmaceuticals | 1 |
| Amgen | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Atypical Hemolytic Uremic Syndrome | 45 |
| Thrombotic Microangiopathies | 13 |
| Glomerulonephritis, Membranoproliferative | 3 |
| Hemolytic-Uremic Syndrome | 3 |
| Kidney Diseases | 3 |
| Thrombocytopenia | 3 |
| Anemia, Hemolytic | 2 |
| Cystinosis | 2 |
| Denys-Drash Syndrome | 2 |
| Glomerulonephritis, IGA | 2 |
Trials
Showing 26 to 45 of 45. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.